BACKGROUND: Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050. METHODS: Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer. FINDINGS: In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by -5·6% (-12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3). INTERPRETATION: Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment. FUNDING: Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.

Zobrazit více v PubMed

Global Burden of Disease 2019 Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncology 2022; 8: 420–44. PubMed PMC

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204–22. PubMed PMC

Ginsburg O, Vanderpuye V, Beddoe AM, et al. Women, power, and cancer: a Lancet Commission. The Lancet 2023; 402: 2113–66. PubMed

Ngwa W, Addai BW, Adewole I, et al. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. The Lancet Oncology 2022; 23: e251–312. PubMed PMC

Lawler M, Davies L, Oberst S, et al. European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission. The Lancet Oncology 2023; 24: e11–56. PubMed

Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. The Lancet Oncology 2020; 21: e185–224. PubMed

Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. The Lancet Oncology 2015; 16: 1405–38. PubMed

Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. The Lancet Oncology 2011; 12: 933–80. PubMed

Rubin G, Berendsen A, Crawford SM, et al. The expanding role of primary care in cancer control. The Lancet Oncology 2015; 16: 1231–72. PubMed

World Health Organization. The Global Initiative for Childhood Cancer. https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer (accessed Oct 11, 2024).

World Health Organization. The Global Breast Cancer Initiative. https://www.who.int/initiatives/global-breast-cancer-initiative (accessed Oct 11, 2024).

World Health Organization. Cervical Cancer Elimination Initiative. https://www.who.int/initiatives/cervical-cancer-elimination-initiative (accessed Oct 11, 2024).

World Health Organization. SDG Target 3.4. Noncommunicable diseases and mental health: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.4-noncommunicable-diseases-and-mental-health (accessed Oct 11, 2024).

Bennett JE, Kontis V, Mathers CD, et al. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. The Lancet 2020; 396: 918–34. PubMed PMC

Teglia F, Angelini M, Astolfi L, Casolari G, Boffetta P. Global Association of COVID-19 Pandemic Measures With Cancer Screening: A Systematic Review and Meta-analysis. JAMA Oncol 2022; 8: 1287–93. PubMed PMC

World Health Organization. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment. https://www.who.int/publications/i/item/9789240010291 (accessed Oct 11, 2024).

Riera R, Bagattini ÂM, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review. JCO Glob Oncol 2021; 7: 311–23. PubMed PMC

Angelini M, Teglia F, Astolfi L, Casolari G, Boffetta P. Decrease of cancer diagnosis during COVID-19 pandemic: a systematic review and meta-analysis. Eur J Epidemiol 2023; 38: 31–8. PubMed PMC

Dos-Santos-Silva I, Gupta S, Orem J, Shulman LN. Global disparities in access to cancer care. Commun Med (Lond) 2022; 2: 31. PubMed PMC

Molassiotis A, Yates P, Li Q, et al. Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study. Annals of oncology : official journal of the European Society for Medical Oncology 2017; 28. https://pubmed.ncbi.nlm.nih.gov/28961835/ (accessed Oct 11, 2024). PubMed

Beaglehole R, Bonita R, Magnusson R. Global cancer prevention: an important pathway to global health and development. Public Health 2011; 125: 821–31. PubMed

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024; 74: 229–63. PubMed

GBD 2023 Disease and Injury and Risk Factor Collaborators. Non-fatal burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet (in review). . PubMed PMC

GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet (in review). . PubMed PMC

GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2133–61. PubMed PMC

GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2100–32. PubMed PMC

GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2204–56. PubMed PMC

Institute for Health Metrics and Evaluation. Protocol for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). https://www.healthdata.org/research-analysis/about-gbd/protocol (accessed Jan 11, 2024).

Stevens G, Alkema L, Black R, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. The Lancet 2016; 388: 19–23. PubMed

The World Bank. World Bank Country and Lending Groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed Oct 11, 2024).

Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr 2012; 10: 1. PubMed PMC

GBD 2023 Demographics Collaborators. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet (in review). . PubMed PMC

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. PubMed PMC

Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed Constrained Mixed Effects Models: Formulations and Algorithms. Journal of Computational and Graphical Statistics 2021; 30: 544–56.

World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. https://www.who.int/publications/i/item/9789241506236 (accessed Oct 11, 2024).

Casolino R, Mikkelsen B, Ilbawi A. Elevating cancer on the global health agenda: towards the fourth high-level meeting on NCDs 2025. Annals of Oncology 2024; 35: 933–5. PubMed

Institute for Health Metrics and Evaluation. Financing Global Health 2023: The Future of Health Financing in the Post-Pandemic Era. https://www.healthdata.org/research-analysis/library/financing-global-health-2023-future-health-financing-post-pandemic-era (accessed Oct 11, 2024).

Micah AE, Bhangdia K, Cogswell IE, et al. Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026. The Lancet Global Health 2023; 11: e385–413. PubMed PMC

Khan G, Fitzmaurice C, Naghavi M, Ahmed LA. Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990–2017. BMJ Open 2020; 10: e037505. PubMed PMC

Nugent R A Chronology of Global Assistance Funding for NCD. Global Heart 2016; 11. https://globalheartjournal.com/articles/10.1016/j.gheart.2016.10.027 (accessed Oct 11, 2024). PubMed DOI

Jailobaeva K, Falconer J, Loffreda G, Arakelyan S, Witter S, Ager A. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. Globalization and Health 2021; 17: 68. PubMed PMC

Allemani C, Matsuda T, Carlo VD, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet 2018; 391: 1023–75. PubMed PMC

Soerjomataram I, Cabasag C, Bardot A, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. The Lancet Oncology 2023; 24: 22–32. PubMed

Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. The Lancet Oncology 2019; 20: 1493–505. PubMed PMC

Oar A, Moraes FY, Romero Y, Ilbawi A, Yap ML. Core elements of national cancer control plans: a tool to support plan development and review. The Lancet Oncology 2019; 20: e645–52. PubMed

Romero Y, Trapani D, Johnson S, et al. National cancer control plans: a global analysis. The Lancet Oncology 2018; 19: e546–55. PubMed

Gelband H, Sankaranarayanan R, Gauvreau CL, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. The Lancet 2016; 387: 2133–44. PubMed

World Health Organization. Best buys. World Health Organization - Regional Office for the Eastern Mediterranean. http://www.emro.who.int/noncommunicable-diseases/publications/factsheets.html (accessed Oct 11, 2024).

Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. Lancet Oncol 2021; 22: e541–9. PubMed

ACTION Study Group. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC medicine 2015; 13. https://pubmed.ncbi.nlm.nih.gov/26282128/ (accessed Oct 11, 2024). PubMed PMC

Smith GL, Banegas MP, Acquati C, et al. Navigating financial toxicity in patients with cancer: A multidisciplinary management approach. CA Cancer J Clin 2022; 72: 437–53. PubMed

Kazzi K, Chino F, Kazzi B, et al. Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; 30. https://pubmed.ncbi.nlm.nih.gov/35877007/ (accessed Oct 11, 2024). PubMed

Ritter J, Allen S, Cohen PD, et al. Financial hardship in families of children or adolescents with cancer: a systematic literature review. Lancet Oncol 2023; 24: e364–75. PubMed PMC

Jan S, Laba T-L, Essue BM, et al. Action to address the household economic burden of non-communicable diseases. The Lancet 2018; 391: 2047–58. PubMed

Watkins DA, Jamison DT, Mills A, et al. Universal Health Coverage and Essential Packages of Care. In: Jamison DT, Gelband H, Horton S, et al. , eds. Disease Control Priorities: Improving Health and Reducing Poverty, 3rd edn. Washington (DC): The International Bank for Reconstruction and Development / The World Bank, 2017. http://www.ncbi.nlm.nih.gov/books/NBK525285/ (accessed Oct 11, 2024).

Tucker-Seeley R, Abu-Khalaf M, Bona K, et al. Social Determinants of Health and Cancer Care: An ASCO Policy Statement. JCO Oncol Pract 2024; 20: 621–30. PubMed

Lunn RM, Mehta SS, Jahnke GD, Wang A, Wolfe MS, Berridge BR. Cancer Hazard Evaluations for Contemporary Needs: Highlights From New National Toxicology Evaluations and Methodological Advancements. JNCI: Journal of the National Cancer Institute 2022; 114: 1441–8. PubMed PMC

Kickbusch I, Allen L, Franz C. The commercial determinants of health. The Lancet Global Health 2016; 4: e895–6. PubMed

U.S. National Cancer Institute and World Health Organization. The Economics of Tobacco and Tobacco Control. National Cancer Institute Tobacco Control Monograph 21. NIH Publication No. 16-CA-8029A. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; and Geneva, CH: World Health Organization; 2016. https://cancercontrol.cancer.gov/brp/tcrb/monographs/monograph-21.

World Health Organization. MPOWER. https://www.who.int/initiatives/mpower (accessed Oct 11, 2024).

Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383: 1340–8. PubMed

World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. https://www.who.int/publications/i/item/who-wer9750-645-672 (accessed Oct 11, 2024).

Sankaranarayanan R Screening for Cancer in Low- and Middle-Income Countries. Annals of Global Health 2014; 80: 412–7. PubMed

Sedhom R, Gyawali B. When Is a Suboptimal Approach to Cancer Screening Better Than None? AMA Journal of Ethics 2020; 22: 93–101. PubMed

Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modelling study. Lancet 2014; 384: 427–37. PubMed

Friel S, Marmot M, Bell R, Houweling TA, Taylor S. WHO Commission on Social Determinants of Health: Closing the gap in a generation. Institute of Health Equity. https://www.instituteofhealthequity.org/resources-reports/commission-on-social-determinants-of-health-closing-the-gap-in-a-generation (accessed Oct 11, 2024).

World Health Organization International Agency for Research on Cancer. Global Cancer Observatory. https://gco.iarc.fr/ (accessed Oct 11, 2024).

Naghavi M, Richards N, Chowdhury H, et al. Improving the quality of cause of death data for public health policy: are all ‘garbage’ codes equally problematic? BMC Medicine 2020; 18: 55. PubMed PMC

World Health Organization International Agency for Research on Cancer. About the GICR. The Global Initiative for Cancer Registry Development. https://gicr.iarc.fr/about-the-gicr/ (accessed Oct 11, 2024).

Rumgay H, Shield K, Charvat H, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. The Lancet Oncology 2021; 22: 1071–80. PubMed PMC

Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. The Lancet Oncology 2015; 16: 36–46. PubMed PMC

World Health Organization International Agency for Research on Cancer. Cancer Tomorrow. https://gco.iarc.who.int/today/ (accessed Oct 11, 2024).

Thrush A, Hyder A. The neglected burden of caregiving in low- and middle-income countries. Disability and Health Journal 2014; 7: 262–72. PubMed

Johnson SE, Samson M. Cancer stigma: the need for policy and programmatic action. JNCI Monographs 2024; 2024: 45–50. PubMed PMC

Guida F, Kidman R, Ferlay J, et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med 2022; 28: 2563–72. PubMed PMC